The Dietary Approaches to Stop Hypertension, or DASH, diet was originally engineered to lower blood pressure, emphasizing fruits, vegetables, whole grains, low-fat dairy, and reduced sodium. But nutrition scientists have long suspected that the pattern could do more than protect the cardiovascular system. Its high fiber content, favorable fatty acid profile, and low glycemic load make it a plausible candidate for tackling the insulin resistance that sits at the metabolic heart of PCOS. The Iranian team took the hypothesis a step further by enriching the DASH framework with legumes, foods packed with plant protein, soluble fiber, and bioactive compounds that may independently improve glucose handling and lipid metabolism. The logic was simple: if the DASH diet is good, a legume-loaded variant might be better.

To test that idea, the researchers designed a rigorously structured randomized controlled trial. Fifty-four women with PCOS, aged 20 to 50 years, were enrolled in Yazd and randomly assigned to either the legume-based DASH diet or a control diet for 16 weeks. Crucially, both groups received calorie-restricted meal plans with an energy deficit of 500 to 700 kilocalories per day, meaning the comparison was not simply about eating less. The two diets differed in their overall dietary pattern and macronutrient composition, isolating the specific effect of the legume-enriched DASH approach. Of the randomized participants, 47 completed the full study, with 25 in the intervention arm and 22 in the control arm.

The methodological rigor of the trial deserves attention. The investigators analyzed their results using analysis of covariance, adjusting for baseline values of each outcome, changes in total energy intake, and physical activity levels, ensuring that observed differences were not merely artifacts of who started where or who moved more. All analyses followed the intention-to-treat principle, and multiple imputation was used to handle missing data, a statistical technique that fills gaps in a way that preserves the integrity of the randomization. The trial was registered prospectively in the Iranian Registry of Clinical Trials on June 12, 2023, and the study was conducted in accordance with the Declaration of Helsinki with ethics approval from the university’s research ethics committee.

The headline findings are striking in their specificity. Compared with the control diet, the legume-based DASH intervention produced statistically significant improvements in weight, with a partial eta-squared effect size of 0.11, and in waist circumference, with a partial eta-squared of 0.10, both at P values of 0.02. Hip circumference also improved significantly at P equals 0.03. These are not trivial effects; in the language of clinical research, partial eta-squared values in this range suggest moderate effects that could translate into meaningful clinical differences for patients. For women with PCOS, central adiposity is particularly consequential, because abdominal fat amplifies the insulin resistance that drives the syndrome’s hormonal chaos.

Perhaps the most patient-relevant result was the improvement in menstrual cycle duration, which reached statistical significance at P equals 0.02 with a partial eta-squared of 0.098. Irregular or absent ovulation is one of the most distressing features of PCOS, a leading cause of anovulatory infertility, and any dietary intervention that nudges cycles toward regularity carries real clinical weight. The lipid profile also responded favorably: high-density lipoprotein cholesterol, the protective HDL-C, improved significantly at P equals 0.04, and low-density lipoprotein cholesterol, the atherogenic LDL-C, showed one of the strongest effects in the trial at P equals 0.006 with a partial eta-squared of 0.14. Given that women with PCOS face elevated long-term cardiovascular risk, shifts in these lipid fractions could matter well beyond the 16-week study window.

Yet the trial is equally notable for what it did not find. The prespecified primary outcome, insulin resistance as measured by the homeostatic model assessment, or HOMA-IR, showed no significant adjusted between-group difference. Neither did fasting blood sugar, fasting insulin, the quantitative insulin sensitivity check index known as QUICKI, triglycerides, total cholesterol, or free testosterone. For an intervention explicitly designed to target the metabolic underpinnings of PCOS, the absence of glycemic improvement is a sobering result, and the failure to move free testosterone, the androgen most closely tied to symptoms like hirsutism and acne, will temper enthusiasm among clinicians hoping for a dietary fix for hyperandrogenism.

How should these null findings be interpreted? The authors are careful in their conclusion, stating that a legume-based DASH dietary pattern may improve anthropometric measures, menstrual cycle duration, and selected lipid parameters, particularly HDL-C and LDL-C, in women with PCOS and overweight or obesity, while acknowledging that the intervention did not significantly improve HOMA-IR or other glycemic indices and free testosterone over 16 weeks. Several possibilities merit consideration. Sixteen weeks may simply be too short a horizon for insulin sensitivity and androgen production to shift detectably, especially if the improvements in adiposity needed more time to cascade into hormonal change. The modest sample size of 47 completers also limits statistical power for outcomes with high inter-individual variability, and the calorie restriction in both arms may have blunted between-group differences by improving metabolic parameters across the board.

The study’s design also raises broader questions about how dietary interventions for PCOS should be evaluated. By matching both groups for calorie deficit, the trial isolated the effect of dietary pattern rather than energy restriction, which is scientifically elegant but clinically nuanced: in the real world, the legume-based DASH diet would be deployed alongside weight loss, and its benefits might compound. The significant effects on weight, waist circumference, and menstrual cycle duration, achieved against an active control that was itself calorie-restricted, suggest the dietary pattern contributes something beyond simple caloric arithmetic. Whether that contribution stems from the legumes themselves, the fiber density, the plant protein, the low glycemic load of the overall pattern, or an interaction among these factors cannot be disentangled from this trial alone.

For the millions of women living with PCOS worldwide, the practical message is cautiously encouraging. A legume-enriched DASH diet, rich in beans, lentils, chickpeas, vegetables, fruits, and whole grains, appears to be a safe and beneficial pattern that improves body composition, cholesterol fractions, and menstrual regularity, even if it does not yet demonstrate the power to reverse insulin resistance or lower free testosterone within four months. Future trials with larger samples, longer durations, and perhaps direct comparisons of legume-enriched versus standard DASH patterns will be needed to pin down the active ingredients. In the meantime, this trial adds a valuable, rigorously controlled data point to the growing evidence that what women with PCOS eat, not just how much, shapes their metabolic and reproductive health.

Subject of Research: Effects of a legume-based DASH diet on metabolic and hormonal outcomes in women with polycystic ovary syndrome

Article Title: Effects of legume-based DASH diet on anthropometric factors, glucose/lipid profiles and free testosterone level in women with polycystic ovary syndrome (PCOS): a randomized clinical trial

Article References: Bolukyazdi, M., Ghadiri-Anari, A., Fallahzadeh, H., & Nadjarzadeh, A. (2026). Effects of legume-based DASH diet on anthropometric factors, glucose/lipid profiles and free testosterone level in women with polycystic ovary syndrome (PCOS): a randomized clinical trial. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02291-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02291-8

Keywords: PCOS, DASH diet, legumes, insulin resistance, free testosterone, lipid profile, menstrual cycle, randomized controlled trial, women's health, nutrition, obesity, endocrinology